{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:22:11Z","timestamp":1791926531817,"version":"4.3.4"},"reference-count":50,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2017,11,26]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Operative link on gastritis assessment (OLGA) staging for gastritis ranks the risk for gastric cancer (GC) in progressive stages (0\u2013IV). This prospective study aimed at quantifying the cancer risk associated with each gastritis stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>\n                      A cohort of 1755 consecutive patients with dyspepsia underwent initial (T-0) oesophagogastroduodenoscopy with mapped gastric biopsies, OLGA staging and assessment of\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      infection. Patients were followed for 55 months (median); patients with stages II III and IV underwent a second endoscopy\/restaging (T-1), and those with stages 0 and I were followed clinically and through in-depth clinical and record checking. Endpoints were OLGA stage at T-1 and development of gastric epithelial neoplasia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At T-0, 77.6% of patients had stage 0, 14.4% stage I, 5.1% stage II, 2.1% stage III and 0.85% stage IV.\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection was detected in 603 patients at T-0 and successfully eradicated in 602 of them; 220 had a documented history of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication; and 932 were\n                      <jats:italic>H. pylori<\/jats:italic>\n                      na\u00efve-negative. Incident neoplastic lesions (prevalence=0.4%; low-grade intraepithelial neoplasia (IEN)=4; high-grade IEN=1; GC=2) developed exclusively in patients with stages III\u2013IV. The risk for epithelial neoplasia was null in patients at stages 0, I and II (95% CI 0 to 0.4), 36.5 per 1000 person-years in patients at stage III (95% CI 13.7 to 97.4) and 63.1 per 1000 person-years in patients at stage IV (95% CI 20.3 to 195.6).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This prospective study confirms that OLGA staging reliably predicts the risk for development of gastric epithelial neoplasia. Although no neoplastic lesions arose in\n                      <jats:italic>H. pylori-<\/jats:italic>\n                      na\u00efve patients, the\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication in subjects with advanced stages (III\u2013IV) did not abolish the risk for neoplastic progression.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2017-314600","type":"journal-article","created":{"date-parts":[[2018,1,6]],"date-time":"2018-01-06T12:15:12Z","timestamp":1515240912000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":157,"title":["Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients"],"prefix":"10.1136","volume":"68","author":[{"given":"Massimo","family":"Rugge","sequence":"first","affiliation":[{"name":"Department of Medicine (DIMED), Pathology Unit, University of Padua, Padova, Italy"},{"name":"Veneto Tumor Registry, Veneto Region, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Meggio","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Trento and Rovereto Hospital, Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Pravadelli","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Trento and Rovereto Hospital, Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Barbareschi","sequence":"additional","affiliation":[{"name":"Department of Pathology, St Chiara Hospital, Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED), Pathology Unit, University of Padua, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gentilini","sequence":"additional","affiliation":[{"name":"Tumor Registry of Trento, Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Zorzi","sequence":"additional","affiliation":[{"name":"Veneto Tumor Registry, Veneto Region, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni De","family":"Pretis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Trento and Rovereto Hospital, Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y","family":"Graham","sequence":"additional","affiliation":[{"name":"Department of Medicine, Michael E DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Genta","sequence":"additional","affiliation":[{"name":"Miraca Life Sciences Research Institute, Irving, Texas, USA"},{"name":"Departments of Pathology and Medicine, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,1,6]]},"reference":[{"key":"2025090714583419000_68.1.11.1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308915"},{"key":"2025090714583419000_68.1.11.2","unstructured":"International Agency for Research on Cancer. Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC working group reports. 8 ed. Geneva, Switzerland: WHO Press, World Health Organization, 2014."},{"key":"2025090714583419000_68.1.11.3","first-page":"59","article-title":"Helicobacter pylori infection and gastric adenocarcinoma","volume":"7","author":"Correa","year":"2011","journal-title":"US Gastroenterol Hepatol Rev"},{"key":"2025090714583419000_68.1.11.4","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-016-0506-0"},{"key":"2025090714583419000_68.1.11.5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i18.5191"},{"key":"2025090714583419000_68.1.11.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.01.040"},{"key":"2025090714583419000_68.1.11.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.028"},{"key":"2025090714583419000_68.1.11.8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302084"},{"key":"2025090714583419000_68.1.11.9","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312288"},{"key":"2025090714583419000_68.1.11.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa001999"},{"key":"2025090714583419000_68.1.11.11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrgastro.2013.96","article-title":"Helicobacter pylori research: historical insights and future directions","volume":"10","author":"Fock","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025090714583419000_68.1.11.12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.cgh.2013.10.029","article-title":"Helicobacter pylori eradication and metachronous gastric cancer","volume":"12","author":"Graham","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025090714583419000_68.1.11.13","doi-asserted-by":"crossref","first-page":"11552","DOI":"10.3748\/wjg.v20.i33.11552","article-title":"Metachronous gastric cancer after successful Helicobacter pylori eradication","volume":"20","author":"Shiotani","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025090714583419000_68.1.11.14","unstructured":"Correa P . The biological model of gastric carcinogenesis. IARC Sci Publ 2004:301\u201310."},{"key":"2025090714583419000_68.1.11.15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i19.5903"},{"key":"2025090714583419000_68.1.11.16","doi-asserted-by":"publisher","DOI":"10.15430\/JCP.2015.20.1.25"},{"key":"2025090714583419000_68.1.11.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2008.02.030"},{"key":"2025090714583419000_68.1.11.18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310846"},{"key":"2025090714583419000_68.1.11.19","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0327-x"},{"key":"2025090714583419000_68.1.11.20","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.101"},{"key":"2025090714583419000_68.1.11.21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01301.x"},{"key":"2025090714583419000_68.1.11.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2010.12.017"},{"key":"2025090714583419000_68.1.11.23","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200002000-00001"},{"key":"2025090714583419000_68.1.11.24","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12050"},{"key":"2025090714583419000_68.1.11.25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00428-011-1177-8","article-title":"Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)","volume":"460","author":"Dinis-Ribeiro","year":"2012","journal-title":"Virchows Arch"},{"key":"2025090714583419000_68.1.11.26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309252"},{"key":"2025090714583419000_68.1.11.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2015.06.010"},{"key":"2025090714583419000_68.1.11.28","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000065"},{"key":"2025090714583419000_68.1.11.29","doi-asserted-by":"crossref","unstructured":"Mera RM , Bravo LE , Camargo MC , et al . Dynamics of helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. In Press. 2017:gutjnl-2016-311685.doi:10.1136\/gutjnl-2016-311685","DOI":"10.1136\/gutjnl-2016-311685"},{"key":"2025090714583419000_68.1.11.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2009.12.029"},{"key":"2025090714583419000_68.1.11.31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/hel.12112","article-title":"OLGA and OLGIM stage distribution according to age and Helicobacter pylori status in the Korean population","volume":"19","author":"Nam","year":"2014","journal-title":"Helicobacter"},{"key":"2025090714583419000_68.1.11.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2012.12.007"},{"key":"2025090714583419000_68.1.11.33","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.bpg.2014.09.002","article-title":"Individual risk stratification of gastric cancer: evolving concepts and their impact on clinical practice","volume":"28","author":"Rugge","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2025090714583419000_68.1.11.34","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1365-2036.2010.04277.x","article-title":"Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study","volume":"31","author":"Rugge","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2025090714583419000_68.1.11.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2004.12.008"},{"key":"2025090714583419000_68.1.11.36","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106666"},{"key":"2025090714583419000_68.1.11.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(11)60593-8"},{"key":"2025090714583419000_68.1.11.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2008.00599.x"},{"key":"2025090714583419000_68.1.11.39","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.3748\/wjg.v22.i13.3670","article-title":"Operative link on gastritis assessment stage is an appropriate predictor of early gastric cancer","volume":"22","author":"Zhou","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2025090714583419000_68.1.11.40","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199610000-00001"},{"key":"2025090714583419000_68.1.11.41","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"},{"key":"2025090714583419000_68.1.11.42","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950801)76:3<376::AID-CNCR2820760305>3.0.CO;2-A"},{"key":"2025090714583419000_68.1.11.43","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.15"},{"key":"2025090714583419000_68.1.11.44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.gtc.2015.05.006","article-title":"When is endoscopic follow-up appropriate after helicobacter pylori eradication therapy?","volume":"44","author":"Kuipers","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"2025090714583419000_68.1.11.45","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.512"},{"key":"2025090714583419000_68.1.11.46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.gtc.2015.05.009","article-title":"Gastric cancer risk in patients with helicobacter pylori infection and following its eradication","volume":"44","author":"Rugge","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"2025090714583419000_68.1.11.47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/den.12483","article-title":"OLGA- and OLGIM-based staging of gastritis using narrow-band imaging magnifying endoscopy","volume":"27","author":"Saka","year":"2015","journal-title":"Dig Endosc"},{"key":"2025090714583419000_68.1.11.48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2011.00827.x"},{"key":"2025090714583419000_68.1.11.49","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12145"},{"key":"2025090714583419000_68.1.11.50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ijc.30700","article-title":"Gastric microbiota features associated with cancer risk factors and clinical outcomes: a pilot study in gastric cardia cancer patients from Shanxi, China","volume":"141","author":"Yu","year":"2017","journal-title":"Int J Cancer"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2017-314600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:58:46Z","timestamp":1757282326000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2017-314600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,6]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,7]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/gutjnl-2017-314600"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2017-314600","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732410880.793555905","asserted-by":"object"}]},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,6]]}}}